Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy (AT-TARGET-IT)

F

Federico II University

Status

Enrolling

Conditions

Hypercholesterolemia

Treatments

Drug: Repatha (evolocumab); Praluent (alirocumab)

Study type

Observational

Funder types

Other

Identifiers

NCT05430828
264/20

Details and patient eligibility

About

Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.

Enrollment

2,000 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients under PCSK9 inhibitor treatment.

Exclusion criteria

  • Age < 18 years o > 80 years;
  • Patients who refuse to participate and to sign informed consent.

Trial design

2,000 participants in 1 patient group

Group 1
Description:
Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).
Treatment:
Drug: Repatha (evolocumab); Praluent (alirocumab)

Trial contacts and locations

27

Loading...

Central trial contact

Pasquale Perrone Filardi, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems